Imatinib Mesylate 400mg Tablet

Imatinib Mesylate 400mg Tablet is a prescription targeted anticancer therapy classified as a tyrosine kinase inhibitor (TKI). It is extensively prescribed in oncology for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). This oral tablet formulation ensures convenient administration while delivering consistent therapeutic action under specialist medical supervision.

Imatinib works by selectively inhibiting abnormal tyrosine kinase enzymes responsible for uncontrolled cancer cell growth. Blocking these disease-causing signals helps slow tumor progression, reduce cancer cell proliferation, and support long-term disease control. Its targeted mechanism allows effective treatment with reduced impact on healthy cells compared to conventional chemotherapy.

Imatinib Mesylate 400 mg Tablets product ensures reliable potency, safety, and therapeutic consistency. This prescription-only oncology medication must be taken exactly as directed by an oncologist, with regular monitoring to achieve optimal treatment outcomes in eligible patients. Its targeted mechanism of action helps improve long-term disease control while supporting better quality of life during treatment.

Product Features

• Targeted anticancer therapy tablet
• Contains Imatinib Mesylate 400 mg
• Used in CML and GIST treatment
• Tyrosine kinase inhibitor (TKI)
• Oral tablet dosage form
• Manufactured under strict pharmaceutical quality standards
• Ensures consistent potency and efficacy
• Prescription-required oncology medicine

How It Helps

• Blocks abnormal tyrosine kinase enzymes that drive cancer cell growth
• Helps control disease progression in chronic myeloid leukemia (CML)
• Inhibits tumor cell signaling in gastrointestinal stromal tumors (GIST)
• Supports targeted cancer treatment with reduced impact on healthy cells